3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Hepatocellular
37
Carcinoma, Non-Small-Cell Lung
29
Triple Negative Breast Neoplasms
23
Nasopharyngeal Carcinoma
23
Stomach Neoplasms
21
Esophageal Squamous Cell Carcinoma
19
Esophageal Neoplasms
19
Breast Neoplasms
18
Squamous Cell Carcinoma of Head and Neck
14
Uterine Cervical Neoplasms
12
Colorectal Neoplasms
12
Sarcoma
10
Pancreatic Neoplasms
9
Lung Neoplasms
9
Recurrence
7
Neoplasm Metastasis
7
Melanoma
6
Hodgkin Disease
6
Cholangiocarcinoma
6
Liver Neoplasms
5
Biliary Tract Neoplasms
5
Small Cell Lung Carcinoma
4
Osteosarcoma
4
Neoplasms
4
Advanced Solid Tumor
4
Advanced Gastric Cancer
4
Solid Tumor
3
Respiratory Tract Diseases
3
Rectal Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Interventions
lenvatinib
1
camrelizumab
1
apatinib
1
Cyclophosphamide
1
Albumin-Bound Paclitaxel
1
ALT-803
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Advanced Triple Negative Breast Cancer
×
camrelizumab
×
Clear all
NCT06849492
2025-02-27
SHIFT-001
Fudan University
Phase 2
Not yet recruiting
120 enrolled